Front Oncol: Efficacy of low-dose nab-paclitaxel combined with PD-1 inhibitor (tislelizumab) in elderly patients with advanced non-small cell lung cancer (NSCLC)

Recently, a team from Nanjing Medical University conducted a phase II clinical study, mainly to evaluate the use of low-dose nab-paclitaxel combined with PD-1 inhibitor (tislelizumab) in elderly patients with advanced non-small cell lung cancer (NSCLC).
efficacy and safety
.

The results were published in the journal Frontiers in Oncology

Recently, a team from Nanjing Medical University conducted a phase II clinical study, mainly to evaluate the use of low-dose nab-paclitaxel combined with PD-1 inhibitor (tislelizumab) in elderly patients with advanced non-small cell lung cancer (NSCLC).

This phase II clinical study included metastatic NSCLC aged ≥65 years, who had progressed after receiving ≧1 line of chemotherapy or targeted therapy, and EGFR or ALK positive patients who received ≧1 line of corresponding TKI therapy after progression can also be included
.

The primary endpoints were progression-free survival and safety/tolerability

This phase II clinical study included metastatic NSCLC aged ≥65 years, who had progressed after receiving ≧1 line of chemotherapy or targeted therapy, and EGFR or ALK positive patients who received ≧1 line of corresponding TKI therapy after progression can also be included

Among the 29 patients enrolled from May 2019 to August 2020, 21 (72.
4%) had adenocarcinoma, 17 (58.
6%) had PS=2, and 8 (27.
6%) had asymptomatic brain metastases.
Thirteen cases (44.
8%) were associated with EGFR/ALK positivity
.

Of the 18 patients (62.

Among the 29 patients enrolled from May 2019 to August 2020, 21 (72.

The median progression-free survival (PFS) of patients in the overall cohort was 9.

The median OS was 16.
5 months (95% CI, 10.
8-22.
3 months)
.

In subgroup analyses, median OS was not reached in patients with EGFR/ALK wild-type adenocarcinoma

The median OS was 16.

Partial remission was achieved in 10 patients with an ORR of 34.
5%
.

DCR was 86.

Partial remission was achieved in 10 patients with an ORR of 34.

The median DOR was 9.
8 months (95% CI, 5.
4 to 14.
3 months)
.
Tumor size decreased from baseline in 18 patients (62.
1%) (median change -18%)
.

The median DOR was 9.
8 months (95% CI, 5.
4 to 14.
3 months)
.
Tumor size decreased from baseline in 18 patients (62.
1%) (median change -18%)
.
The median DOR was 9.
8 months (95% CI, 5.
4 to 14.
3 months)
.
Tumor size decreased from baseline in 18 patients (62.
1%) (median change -18%)
.

Seventeen (58.
6%) patients had at least one treatment-related adverse event, and three (10.
3%) patients had grade 3 adverse events
.
There is no level 4 TRAE
.
The most common adverse events were fatigue (20.
7%), pyrexia (17.
2%), abnormal liver function (17.
2%), and rash (17.
2%)
.
Only 1 patient discontinued treatment because of validated TRAE
.

Seventeen (58.
6%) patients had at least one treatment-related adverse event, and three (10.
3%) patients had grade 3 adverse events
.
There is no level 4 TRAE
.
The most common adverse events were fatigue (20.
7%), pyrexia (17.
2%), abnormal liver function (17.
2%), and rash (17.
2%)
.
Only 1 patient discontinued treatment because of validated TRAE
.

In conclusion, the study shows that low-dose nab-paclitaxel combined with tislelizumab is effective and tolerable in elderly patients with advanced NSCLC, including patients with EGFR/ALK mutations
.

In conclusion, the study shows that low-dose nab-paclitaxel combined with tislelizumab is effective and tolerable in elderly patients with advanced NSCLC, including patients with EGFR/ALK mutations
.
Studies have shown that low-dose nab-paclitaxel combined with tislelizumab is effective and tolerable in elderly patients with advanced NSCLC, including patients with EGFR/ALK mutations
.
Studies have shown that low-dose nab-paclitaxel combined with tislelizumab is effective and tolerable in elderly patients with advanced NSCLC, including patients with EGFR/ALK mutations
.

 

Original source:

Original source:

Zhu W, Geng Q, Peng H, Jin Z, Li D, Pu X, Wang G and Jiang H (2022) Effificacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer.
Front.
Oncol.
12:802467.
doi: 10.
3389/fonc.
2022.
802467

Zhu W, Geng Q, Peng H, Jin Z, Li D, Pu X, Wang G and Jiang H (2022) Effificacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer.
Front.
Oncol.
12:802467.
doi: 10.
3389/fonc.
2022.
802467 Leave a comment here